2019 American Transplant Congress
Alemtuzumab Induction in Living Donor Renal Transplantation
The Ohio State University Wexner Medical center, Columbus, OH
*Purpose: About 15% of kidney transplant (KT) recipients receive alemtuzumab (ALM) for induction. The aim of this study was to review outcomes in living donor…2019 American Transplant Congress
Safety Outcomes in Elderly Patients Who Receive Alemtuzumab Induction for Kidney Transplant
Ochsner Clinic Foundation, New Orleans, LA
*Purpose: As a consequence of natural immunosenescence, elderly patients may not require as potent immunosuppression as their younger counterparts. Optimal induction regimens in this population,…2018 American Transplant Congress
A Protocol for the Management of Alemtuzumab Induced Leukopenia in Kidney Transplant Recipients
University of Maryland Medical Center, Baltimore.
Purpose: Leukopenia is a common complication following alemtuzumab induction in kidney transplant recipients (KTR), often limiting its use. Our institution developed a protocol to manage…2018 American Transplant Congress
Microbiology and Outcomes of Febrile Neutropenia Episodes after Kidney Transplant
Medicine, Columbia University Medical Center, New York, NY.
Febrile neutropenia (FN) is a common complication in cancer patients receiving chemotherapy. Neutropenia is common after kidney transplant (KT), but little is known about the…2018 American Transplant Congress
The Impact of Induction Agent on Development of Febrile Neutropenia Following Kidney Transplant
Medicine, Columbia University Medical Center, New York, NY.
Neutropenia is common after kidney transplant (KT), usually due to medication side effects (induction agents maintenance medications, antibiotics), and is associated with worse patient and…2018 American Transplant Congress
Use of Granulocyte Colony-Stimulating Factor for Leukopenia Post-Renal Transplant
Purpose: Leukopenia is a frequent complication in renal transplant recipients (RTRs). Granulocyte colony-stimulating factor (G-CSF) accelerates white blood cell (WBC) count recovery; but, published experience…2017 American Transplant Congress
Down but Not Out: Leucopenia Can Be Safely Treated with Reduction in Immunosuppression without Increasing Risk to the Kidney Allograft.
IntroductionLeucopenia is a growing problem with increasing immunosuppression (IS) in kidney transplantation. Reducing IS in the face of leucopenia is a concern due to the…2017 American Transplant Congress
Neutropenia in Kidney and Liver Transplant Recipients: Risk Factors and Consequences.
Aim: This study aimed to: 1) Define the risk factors associated with neutropenia within the first year post kidney or liver transplantation; 2) Describe the…2017 American Transplant Congress
Neutropenia in Kidney Transplantation: A Hidden Threat to Graft Survival.
Medstar Georgetown Transplant Institute, Washington, DC
IntroductionNeutropenia is a common complication after kidney transplantation resulting in a reduction of immunosuppression and the use of granulocyte colony-stimulating factors (G-CSF) which can increase…2017 American Transplant Congress
Impact of Filgrastim Use on Maintenance Doses of Immunosuppressants and Clinical Outcomes in Renal Transplant Patients.
Introduction: There are limited data assessing the outcomes of filgrastim for the treatment of neutropenia among renal transplant patients. We investigated the association of filgrastim…
American Transplant Congress abstracts